• Explore /
  • Poster
  • / Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <em>CDKN2A</em> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Abstract Poster

Authors

null

Eugene R Ahn

Cancer Treatment Centers of America, Zion, IL

Eugene R Ahn , Pam K. Mangat , Elizabeth Garrett-Mayer , Susan Halabi , Elie G. Dib , Daniel Ernest Haggstrom , Kathryn B. Alguire , Ricardo H. Alvarez , Carmen Julia Calfa , Timothy Lewis Cannon , Pamela A. Crilley , Anu G. Gaba , Alissa S. Marr , Ashish Sangal , Ramya Thota , Kaitlyn R. Antonelli , Samiha Islam , Andrew Lawrence Rygiel , Suanna S. Bruinooge , Richard L. Schilsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02693535

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9041)

DOI

10.1200/JCO.2019.37.15_suppl.9041

Abstract #

9041

Poster Bd #

364

Abstract Disclosures

Similar Posters

First Author: Evan P. Pisick

First Author: Tareq Al Baghdadi

First Author: Carmen Julia Calfa

First Author: Eyal Meiri